Stuart Poulton
Fortuna: 862 871 $ al 31/05/2026
Fortuna: 862 871 $ al 31/05/2026
Stuart Poulton is Chief Development Officer & Executive VP at Karyopharm Therapeutics, Inc. since 2022.
Formerly, Mr. Poulton was Vice President-Clinical Development Operations at AbbVie, Inc. from 2019 to 2022, Executive Director-Global Program Management at Amgen, Inc. from 2013 to 2016, and Head-Clinical Operations at Eli Lilly & Co. Education includes graduate studies at The University of New South Wales and undergraduate studies at The University of Sydney.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 14/05/2026 | 94.821 ( 0,42 % ) | 862 871 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Corporate Officer/Principal | 01/02/2022 |
| Empresas | Cargo | Fin |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01/01/2022 |
| AMGEN INC. | Corporate Officer/Principal | 01/01/2016 |
| ELI LILLY AND COMPANY | Director Técnico/Científico/I+D | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 6 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
AbbVie, Inc.
AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
The University of New South Wales
The University of New South Wales Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Sydney
The University of Sydney Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.